226 related articles for article (PubMed ID: 30477316)
1. Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1.
Hickey RD; Nicolas CT; Allen K; Mao S; Elgilani F; Glorioso J; Amiot B; VanLith C; Guthman R; Du Z; Chen H; Harding CO; Kaiser RA; Nyberg SL; Lillegard JB
Cell Transplant; 2019 Jan; 28(1):79-88. PubMed ID: 30477316
[TBL] [Abstract][Full Text] [Related]
2. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
[TBL] [Abstract][Full Text] [Related]
3. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
4. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
5. In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.
Nicolas CT; VanLith CJ; Hickey RD; Du Z; Hillin LG; Guthman RM; Cao WJ; Haugo B; Lillegard A; Roy D; Bhagwate A; O'Brien D; Kocher JP; Kaiser RA; Russell SJ; Lillegard JB
Nat Commun; 2022 Aug; 13(1):5012. PubMed ID: 36008405
[TBL] [Abstract][Full Text] [Related]
6. Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
Zhang L; Shao Y; Li L; Tian F; Cen J; Chen X; Hu D; Zhou Y; Xie W; Zheng Y; Ji Y; Liu M; Li D; Hui L
Sci Rep; 2016 Aug; 6():31460. PubMed ID: 27510266
[TBL] [Abstract][Full Text] [Related]
7. Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease.
Hickey RD; Mao SA; Glorioso J; Lillegard JB; Fisher JE; Amiot B; Rinaldo P; Harding CO; Marler R; Finegold MJ; Grompe M; Nyberg SL
Stem Cell Res; 2014 Jul; 13(1):144-53. PubMed ID: 24879068
[TBL] [Abstract][Full Text] [Related]
8. Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1.
Elgilani F; Mao SA; Glorioso JM; Yin M; Iankov ID; Singh A; Amiot B; Rinaldo P; Marler RJ; Ehman RL; Grompe M; Lillegard JB; Hickey RD; Nyberg SL
Am J Pathol; 2017 Jan; 187(1):33-41. PubMed ID: 27855279
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte spheroids as an alternative to single cells for transplantation after ex vivo gene therapy in mice and pig models.
Nicolas CT; Hickey RD; Allen KL; Du Z; Guthman RM; Kaiser RA; Amiot B; Bansal A; Pandey MK; Suksanpaisan L; DeGrado TR; Nyberg SL; Lillegard JB
Surgery; 2018 Sep; 164(3):473-481. PubMed ID: 29884476
[TBL] [Abstract][Full Text] [Related]
10. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
[TBL] [Abstract][Full Text] [Related]
11. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
Wu G; Liu N; Rittelmeyer I; Sharma AD; Sgodda M; Zaehres H; Bleidissel M; Greber B; Gentile L; Han DW; Rudolph C; Steinemann D; Schambach A; Ott M; Schöler HR; Cantz T
PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
[TBL] [Abstract][Full Text] [Related]
13. Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I.
Cheng Q; Wei T; Jia Y; Farbiak L; Zhou K; Zhang S; Wei Y; Zhu H; Siegwart DJ
Adv Mater; 2018 Dec; 30(52):e1805308. PubMed ID: 30368954
[TBL] [Abstract][Full Text] [Related]
14. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I.
Gil-Martínez J; Macias I; Unione L; Bernardo-Seisdedos G; Lopitz-Otsoa F; Fernandez-Ramos D; Lain A; Sanz-Parra A; Mato JM; Millet O
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670179
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
17.
Nicolas CT; Kaiser RA; Hickey RD; Allen KL; Du Z; VanLith CJ; Guthman RM; Amiot B; Suksanpaisan L; Han B; Francipane MG; Cheikhi A; Jiang H; Bansal A; Pandey MK; Garg I; Lowe V; Bhagwate A; O'Brien D; Kocher JA; DeGrado TR; Nyberg SL; Lagasse E; Lillegard JB
Mol Ther Methods Clin Dev; 2020 Sep; 18():738-750. PubMed ID: 32913881
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
19. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
20. Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I.
Wilber A; Wangensteen KJ; Chen Y; Zhuo L; Frandsen JL; Bell JB; Chen ZJ; Ekker SC; McIvor RS; Wang X
Mol Ther; 2007 Jul; 15(7):1280-7. PubMed ID: 17440442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
